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Metastasisbetween epithelial and endothelial cells, tight junctions (TJ) are well known as
functioning as a control for the paracellular diffusion of ions and certain molecules. It has however, become
increasingly apparent that the TJ has a vital role in maintaining cell to cell integrity and that the loss of
cohesion of the structure can lead to invasion and thus metastasis of cancer cells. This article will present
data showing how modulation of expression of TJ molecules results in key changes in TJ barrier function
leading to the successful metastasis of a number of different cancer types.
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Tight junctions (TJ) govern the permeability of epithelial and
endothelial cells and are the most topical structures of these cell types
[1–3]. It is a region where the plasma membrane of adjacent cells
forms a series of contacts that appear to completely occlude the
extracellular space thus creating an intercellular barrier and intra-
membrane diffusion fence [4].
TJ in endothelial cells function as a barrier through which
molecules and inﬂammatory cells can pass. In epithelial cells the TJ
functions in an adhesive manner and can prevent cell dissociation [5].
An important step in the formation of cancer metastases is interaction
and penetration of the vascular endothelium by dissociated cancer
cells. TJ are therefore the ﬁrst barrier that cancer cells must overcome
in order to metastasize. We have previously demonstrated that TJ of
vascular endothelium in vivo function as a barrier between blood and
tissues against metastatic cancer cells [6].
Early studies have demonstrated a correlation between the
reduction of TJ and tumor differentiation and experimental evidence
has emerged to place TJ in the frontline as the structure that cancer
cells must overcome in order to metastasize [6–9]. Although a
considerable body of work exists on TJ and their role in a number of
diseases, following the early work of Martinez-Paloma [10] and others
[11,12] it is only in the last few years that there has been an upsurge in
studies investigating their possible role in tumorigenesis. To date,
most of the work has been concentrated on cell lines and to a limited
degree on colorectal [13–16] and pancreatic cancers [15–17] and an
increasing number of studies carried out on breast cancer [9,18–24] all
of which will be discussed later.
The expression of TJ proteins may be modulated by growth
factors, cytokines, regulatory mechanisms or promoter methylation.
Regulatory mechanisms may be via the suggested pathway of the
epithelial–mesenchymal-transition (EMT) as the process of acquisi-
tion of an invasive phenotype by tumors of epithelial origin can be
regarded as a pathological version EMT [25,26]. TJ determine
epithelial cell polarity and disappear during EMT. Snail and Slug are
factors thought to be responsible for this loss [27]. Regulation alsooccurs via the Rho GTPase family, which is able to regulate TJ
assembly [28]. Thus the TJ can be regulated in response to
physiological and tissue-speciﬁc requirements [4]. TJ are able to
rapidly change their permeability and functional properties in
response to stimuli, permitting dynamic ﬂuxes of ions and solutes
in addition to the passage of whole cells [29,30].
This article will review the recent progress in elucidating the role
of TJ in the invasion and metastasis of cancer via changes barrier
function due to modulations in expression of TJ proteins and
alterations in the structure of the TJ itself. It is apparent that changes
in the function and regulation of TJ in cancer is not just a by-product of
cancer progression but is integral to its formation and persistence,
eventually enabling metastasis and secondary disease. As such, this
area of research is of fundamental importance in the effort to
understand and alleviate this terrible disease.
The changes in both tumor and endothelial cells are necessary for
successful growth and spread of cancer cells and that these changes
are somewhat similar. A change in cancer cells by up-regulation or
down-regulation of relevant TJ proteins results in loss of cell–cell
association, cell contact inhibition, leading to uncontrolled growth,
loss of adhesion to and degradation of the basement. These must be a
concurrent loss of cell–cell association in the endothelium and
modulation of TJ proteins involved in facilitating the passage of the
cancer cells through this barrier.2. TJ molecular structure
Brieﬂy, the TJ has a characteristic structure, appearing as discrete
sites of fusion between the outer plasma membrane of adjacent cells.
When visualized using freeze-fracture, they appear as continuous
intramembrane particle strands in the protoplasmic face with
complimentary grooves in the extracellular face when adjacent cells
are viewed in ultra-thin section electron microscopy [30]. These
completely circumscribe the apices of the cells as a network of
intramembrane ﬁbrils [4] appearing as what is generally described as
a series of “kissing” points.
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molecules that constitute, associate with or regulate TJ [31].
Although a number of proteins were identiﬁed in the mid 1989s,
the list of additional molecules has expanded considerably over
recent years (Table 1). The molecular components of the TJ have
been extensively investigated [3,32] and it is apparent that the
junctions could be reasonably separated into 3 regions: (i) the
integral transmembrane proteins — occludin, claudins and junctional
adhesion molecules (JAM), together with other CTX family members;
(ii) the peripheral or plaque anchoring proteins, often containing
PDZ motifs — zonula occludens (ZO)-1, -2, -3, MAGI-1 etc.; and (iii)
TJ-associated/regulatory proteins — α-catenin, cingulin etc.
The integral transmembrane proteins are the essential adhesion
proteins responsible for correct assembly of the TJ structure and
controlling TJ functions via homotypic and heterotypic interactions.
Successful assembly and maintenance of the TJ is accomplished by
anchorage of the transmembrane proteins by the peripheral or plaque
proteins such as ZO-1 which act as a scaffold to bind the raft of TJ
molecules together and provide the link to the actin cytoskeleton and
the signalling mechanism of the cell. This is in conjunction with the
associated/regulatory proteins.
3. TJ functions
Although cell adhesion to adjacent cells and the extracellular
matrix is key to the organization of epithelium into a tissue, it is vital
to the regulation of cellular processes such as differentiation, gene
expression, motility and growth [33]. These regulatory functions are
mediated by cell adhesion molecules, transmembrane receptors and
cytoskeletal proteins all of which are organized into multimolecular
complexes and the activation of signalling pathways.
The main functions ascribed to the TJ:
(1) The TJ seals the intercellular space and is responsible for the
separation of apical and basolateral ﬂuid compartments of
epithelia and endothelia. The TJ functions as a diffusion
barrier to plasma membrane lipids and proteins, which helps
to deﬁne apical and basolateral membrane domains of these
polarized epithelial and endothelial cells. Therefore the TJ is
crucial for the epithelium to generate chemical and electrical
gradients across the cell monolayer that is necessary for
vectorial transport processes such as absorption and
secretion.
(2) TJ molecules act as intermediates and transducers in cell
signalling, thus playing a role in the processes of polarity, cell
differentiation, cell growth and proliferation.
(3) TJ proteins act as cell–cell adhesion molecules.
(4) The TJ functions as a barrier to cell migration.
Increasing, evidence suggests that the suppression of the malig-
nant phenotype of cells in tumorigenesis is an additional and
important function of the TJ [33]. While the barrier and fenceTable 1
Proteins involved in TJ structure, function and regulation
Integral transmembrane
proteins
Peripheral plaque proteins Associated proteins
Occludin Zonula occludens-1 (ZO-1) Cingulin, 7H6,
Claudins 1–24 ZO-2 Symplekin, ZONAB
Junctional adhesion
molecules (A–C, 4) and
other CTX proteins such
as Coxsackie adenovirus
receptor (CAR)
ZO-3 Rab-13, 19B1, ponsin
MAGI-1, -2, -3 Rab 3B, PKC, l-afadin
MUPP-1 c-src, Gαi-2, Gαi-12,
PAR-3/ASIP α-catenin, Pals, PATJ
PAR-6 PKA, JEAP, Pilt, PTEN,
AF-6/s-afadin ZAK, SCRIB, ITCH,
CASK Rho-GTPases, WNK4, vinculin
CAROMfunctions of TJ have beenwell appreciated, it is only relatively recently
that concept of the TJ as a complex, multiprotein structure with roles
in other cellular processes such as cell polarity, proliferation and
differentiation has been recognized [34]. Moreover, it is becoming
increasingly clear that the development of human cancer is frequently
associated with the failure of epithelial cells to form TJ and to establish
correct apicobasal polarity [35].
4. Cancer invasion, angiogenesis and metastasis
Metastasis, the spread of cancer cells to tissues and organs beyond
where the tumor originated and the formation of new tumors
(secondary and tertiary foci) is the single event that results in the
death of most patients with cancer. At the time of diagnosis of cancer,
at least half of the patients already present clinically detectable
metastatic disease [36]. A higher number of patients will also have
micrometastases that would be beyond conventional detection
techniques.
Thus, metastasis is the most life threatening event in patients with
cancer. The process is composed of a number of sequential events
which must be completed in order for the tumor cell to successfully
metastasize, the so called metastatic cascade. This process contributes
to the complexity of cancer as a multiplex disease. The metastatic
cascade can be broadly separated into three main processes: invasion,
intravasation and extravasation (Fig. 1).
Malignant tumor cells must dissociate from the primary tumor
mass by loss of cell–cell adhesion capacity and invade the surrounding
stroma; the process of invasion. This involves the secretion of
substances to degrade the basement membrane and extracellular
matrix and also the expression/suppression of proteins involved in
the control of motility and migration. The tumor must also initialize
angiogenesis, without which the tumor would fail to develop, as local
diffusion for transport of nutrients to and removal of waste products
from the tumor site would sufﬁce for tumors up to 2 mm in diameter
[37]. An interesting model can be found in Mullin [38], an “epithelial
wounding”model. For tumors to continue to grow, a connection must
be made to the blood supply. The blood vessel within the tumor's
vicinity can then provide a route for the detached cells to enter the
circulatory system and metastasize to distant sites; the process of
intravasation [39,40]. Interaction between the tumor cell and the
surrounding stroma is extremely important in the development of
tumor angiogenesis [41]. The detached tumor cells must enter the
circulatory system and survive the forces involved and the immune
system to arrive intact at a distant site. Once the tumor cell has arrived
at a likely point of intravasation, it interacts with the endothelial cells
by undergoing biochemical interactions (mediated by carbohydrate–
carbohydrate locking reactions, which occur weakly but quickly)
develop adhesion to the endothelial cells to form stronger bonds, and
thus penetrate the endothelium and the basement membrane; the
process of extravasation. The new tumor can then proliferate at this
secondary focus.
Thus, as TJ exist between the cancer cells themselves, the cells of
the stroma and the cells of the endothelium, the TJ is the ﬁrst structure
impeding the path to successful metastasis of the cancer cells. For the
tumor cell to proceed effectively, the TJ structure must be disturbed
and dismantled to enable penetration of the cancer cell.
5. Metastasis and TJ
It is evident that the interaction and penetration of endothelium by
the metastasizing tumor cell is therefore a key step in the formation of
metastasis [28,42,43]. As our knowledge and understanding of the
molecular structure, mechanism of action and function of TJ is
expanded it has become apparent that the TJ can be regarded as a
potentially important target for anti-cancer research and possible area
for future therapeutics.
Fig. 1. Schematic illustrating events in the metastatic cascade.
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Although there are believed to be numerous events contributing to
the process of metastasis, it is widely accepted that the loss of cell–cell
adhesion in neoplastic epithelium is necessary for invasion of
surrounding stromal elements and subsequent metastatic events
[18]. The association between TJ permeability of human epithelium
has been investigated for some time. Tobioka et al. [44] have shown
that the enhancement of TJ function reduced the penetration of tumor
cells through mesothelial cells. Soler et al. [45] examined the
permeability in normal human and rat colon epithelia and in colon
tumors. TER and paracellular inﬂux rate revealed the TJ of colon
tumors – both natural and induced – were “leakier” than those of
normal colon that was suggestive of an increased permeability of
colon epithelium and that a decrease in epithelium barrier function
precedes the development of colon tumors. Host cell signalling
pathways such as phosphorylation of myosin light chain and the
regulation of the TJ proteins claudin-4 and claudin-5 are the results of
Helicobacter pylori induced chronic gastritis and may progress to
gastric cancer [46]. Interestingly, it was noted that DMSO (Dimethyl
sulphate up to 10%) produced no signiﬁcant alteration in TJ
permeability or in the cell–cell TJ complex in Caco2/TC7 colon cancer
cells, an unexpected result as DMSO is usually used to solubilize
poorly soluble drugs in permeation assays [47]. Mullin et al. [48] have
opined that TJ leakiness is a late event in epithelial carcinogenesis but
allows for growth factors in luminal ﬂuid compartments to enter
intercellular and interstitial ﬂuid spaces for the ﬁrst time, binding
receptors located only on the baso-lateral cell surface, causing
changes in epithelial cell kinetics, concluding that TJ leakiness is a
promotional event unique to epithelial tumors. This conclusion was
the result of data showing that adenocarcinomas in rat and human
colon have uniformly leaky TJ, whereas most human colon hyper-
plasic and adenomatous polyps contain non-leaky TJ, though
adenomatous polyps with dysplastic changes did posses leaky TJ.
Moreover, protein kinase C activation and translocation results in
increased permeability of LLC-PK1 cells and failure to regulate this
activation is correlated with multilayered cell growth and persistent
leakiness. Clarke et al. [49] further this by stating that TJ leakinessassociated with protein kinase C activation (and its downstream
effectors) suggests a potentially useful role for TJ leakiness as amarker
for early cancer diagnosis. These protein kinase C activators are all
tumor promoters, which supports the concept of TJ being integral to
the progression of cancer. HGF/SF (hepatocyte growth factor or
scatter factor), a cytokine secreted by stromal cells and key to the
development and progression of cancer, particularly during metas-
tasis has been shown to is capable of modulating expression and
function of TJ molecules in human breast cancer cell lines [23]. HGF
decreased trans-epithelial resistance and increases paracellular
permeability of human breast cancer cell lines, MDA-MB-231 and
MCF-7. Q-PCR showed that HGF modulated the levels of several TJ
molecule (occludin, claudin-1 and -5, JAM-1 and -2) mRNA
transcripts in MDA MB 231 and MCF-7 cells. Western blotting and
immunohistochemistry also showed modulation of expression of the
TJ molecule, occludin. It is suggested that HGF disrupts TJ function in
human breast cancer cells by effecting changes in the expression of TJ
molecules at both the mRNA and protein levels. The conclusion was
that regulation of TJ could be of fundamental importance in the
prevention of metastasis of breast cancer cells (Fig. 2).
Oncogene mutations have also been shown to result in increased
“leakiness” of TJ in cancer. Ras mutations canmodulate the expression
of a number of TJ molecules [50]. The abundance of claudin-2 declined
to undetectable levels in ras-overexpressing cells compared with
vector controls whereas levels of occludin and claudins 1, 4, and 7
increased and the abundance of claudins-3 and -5 remained
unchanged. An increase in extracellular signal-regulated kinase-2
phosphorylation suggests that the downstream effects on the tight
junction may be due to changes in the mitogen-activated protein
kinase signalling pathway and such selective changes in permeability
may inﬂuence tumorigenesis by the types of solutes now able to cross
the epithelial barrier. During epithelial morphogenesis the apically-
localized proteins of the Par (Par3-Par6-aPKC-Cdc42) and Crumbs
groups (Crb3-PALS1-PATJ) and the basolaterally localized proteins of
the Dlg group (Dlg1-Scribble-Lgl) participate in a complex network of
interdependent interactions that deﬁne the position and functional
organization of adherens junctions and tight junctions. Stucke et al.
[51] found an interaction between endogenous hDlg1 and MPP7, a
Fig. 2. Effect of HGF on expression of TJ molecules in human breast cancer cells. (A) Western blots of TJ proteins after HGF treatment. (B) HGF and the increased phosphorylation
status of ZO-1 in human breast cancer cell lines. This suggests deactivation of ZO-1 by HGF. (C) Immuno-staining of human breast cancer cell lines treated with HGF for 1 h. Cells were
stained with ZO-1 or occludin. MCF-7 cells, but not MDA MB 231 cells showed typical TJ pattern staining for ZO-1 and occludin at 0 h. HGF reduced staining of both by 1 h. Both cell
lines show increased cytosolic staining and re-location of occludin and ZO-1 to rufﬂed membrane areas.
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targets to the lateral surface of epithelial cells via its L27N domain,
through an interaction with hDlg1. Loss of either hDlg1 or MPP7 from
epithelial Caco-2 cells results in a signiﬁcant defect in the assembly and
maintenance of functional tight junctions, concluding that the
formation of a complex between hDlg1 and MPP7 promotes epithelial
cell polarity and tight junction formation. It is obvious that all these
factors in the tumormicroenvironment predispose cells toTJ leakiness.
5.2. Penetration of the endothelium by tumor cells
Regulation of vascular permeability is one of the most important
functions of endothelial cells, and endothelial cells from different
organ sites show different degrees of permeability [52]. Tumor blood
vessels are more permeable on macro-molecular diffusion than
normal tissue vessels. However, the cause and mechanism of
hyperpermeability of human vessels had not been clear [52]. Tumorcells release a number of factors that can assist their transmigration
through the endothelium after treating endothelial cells with
conditioned media from a highly invasive and metastatic melanoma
cell line [52], with TJ being irreversibly damaged (as assessed using
TER-trans-epithelial resistance). The invasion and metastasis of rat
oral carcinoma cells can be inhibited by malotilate (MT) through
modiﬁcation of the host endothelial cells [53]. MT did not however
affect the growth of human squamous cell lines (SAS, Ca9-22, HSC-2,
3, 4) through a rat lung endothelial invasion model. MT treatment of
the endothelial cells did inhibit invasion in SAS, Ca9-22 and HSC-4
cells. ZO-1 protein levels were elevated dose dependently, with
enhanced TJ function. HGF has been shown to decrease TER and
increase PCP (paracellular permeability) in human endothelial cells
[2]. NK4, an antagonistic variant of HGF was shown to inhibit this
reduction in TJ function and to inhibit HGF-stimulated invasion of
endothelium by human breast cancer cells (MDA-MB-231) [6]. HGF
decreased the protein expression of ZO-1 and increased tyrosine
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occludin, claudin-1 or claudin-5. NK4 successfully prevented HGF-
derived ZO-1 expression changes.
6. TJ molecules in cancer progression
Most cancers originate from epithelial tissues and are character-
ized by aberrant growth control and loss of differentiation and tissue
architecture. It is a fundamental property of cancer cells that their
mutual adhesiveness is signiﬁcantly weaker than that of normal cells.
Reduced cell–cell interaction allows cancer cells to disobey the social
order, resulting in destruction of overall tissue architecture, the
morphological hallmark of malignancy. Loss of contact inhibition,
which reﬂects disorder in the signal transduction pathways that
connect cell–cell interactions are typical of both early (loss of cell
polarity and growth control) and late (invasion andmetastasis) stages
of tumor progression. An increasing number of studies have shown
that numerous TJ components are directly or indirectly involved in
cancer progression including ZO-1, ZO-2, claudin-7, claudin-1 and
occludin. Highly differentiated adenocarcinomas with well developed
TJ provide an important insight into the usefulness of TJ molecules are
possible prognostic indicators and future targets for therapy. In breast
cancer, ZO-1 has been demonstrated to be decreased in poorly
differentiated tumors and correlated with increasing Grade and TNM
(tumor-nodal) status [24]. Such observations indicate that TJ
molecules could be used to identify poorly differentiated tumors
and hence patients with poor prognosis.
There are a respectable number of reports describing the
dysregulation of transmembrane proteins in human cancers and in
cell lines. This dysregulation can be the result of both up-regulation
and down-regulation of expression, epigenetic changes and changes
in activation and location of the proteins. The following section will
discuss such dysregulation by tumor type.
6.1. Breast cancer
6.1.1. Transmembrane proteins in breast cancer
Claudin-1 (ﬁrst described by [54]) is normally expressed in
mammary gland-derived epithelial cells, but is absent in most
human breast cancer cell lines. Claudin-1 expression was not
detectable in subconﬂuent MDA-MB-435 and MDA-MB-361 breast
cancer cells [9]. Neither of these cell lines expresses occludin protein,
and MDA-MB-435 does not express ZO-1 protein. Claudin-1 retroviral
transduced breast cancer cells showed expression of Claudin-1 at the
usual cell–cell contact sites, suggesting that other proteins may be
able to target claudin-1 to the TJ in the absence of occludin and ZO-1.
Moreover, paracellular permeability was reduced in these transduced
cells. The authors suggest that Claudin-1 gene transfer may be in itself
enough to exert TJ mediated gate function in metastatic breast cancer
cells even in the absence of other TJ associated proteins such as
occludin. This indicates a possible tumor suppressor function. In
sporadic and hereditary breast cancer, there were no genetic changes,
implying that regulatory or epigenetic factors may be involved in the
downregulation of the claudin-1 gene during breast cancer develop-
ment [19].
Claudin-1 cDNA isolated from human mammary epithelial cells
(HMECs) was highly expressed in comparison to low or undetectable
levels of expression in a number of breast tumors and breast cancer
cell lines [19]. This indicated a possible tumor-suppressor effect for
claudin-1. In sporadic tumors and hereditary breast cancer patients,
there was no evidence to support the involvement of aberrant
claudin-1 in breast tumorigenesis. Likewise, in breast cancer cell
lines, no genetic alterations in the promoter or coding sequences were
identiﬁed to explain the loss of claudin-1 expression. It was suggested
that other regulatory or epigenetic factors may be involved in the
downregulation of this gene during breast cancer development.Loss of claudin-7 has been found to correlate with histological
grade in both ductal carcinoma in situ and invasive ductal carcinoma
of the breast [18]. The expression of claudin-7 is lost in both
preneoplastic and invasive ductal carcinoma of the breast occurring
predominately in high grade lesions. Expression is also frequently lost
in LCIS correlating with the increased cellular discohesion observed in
LCIS. Additionally, the majority of IDC cases displaying a low claudin-7
expression have a positive lymph node status. Such ﬁndings suggest
that the loss of claudin-7 may aid in tumor cell dissemination and
augment metastatic potential. Moreover, silencing of claudin-7
expression correlated with promoter hypermethylation in 3/3 breast
cancer cell lines but not in invasive ductal carcinomas (0/5). In
addition, HGF treatment results in disassociation of MCF-7 and T47D
cells in culture, and a loss of claudin-7 expressionwithin 24 h. Sauer et
al. [55] more recently showed that primary and recurrent/metastatic
breast lesions expressed Claudin-7. 46% of cases had full expression
and reduced expression was found in 54%. In cases with reduced
expression, the percentage of stained cells was usually high, and no
smear showed b50% stained tumor cells. The staining pattern was
heterogeneous and always mixed membrane/cytoplasmic. Claudin-7
expression was signiﬁcantly correlated with tumor grading local
recurrences and metastatic diseases, nodal involvement and cellular
cohesion in invasive carcinomas, but not with tumor size or subtype.
Tokes et al. [56] compared levels of protein andmRNAexpression of
three members of the claudin family in malignant breast tumors and
benign lesions. Altogether, 56 sections from 52 surgically resected
breast specimens were analyzed for claudin-1, -3 and -4 expression by
immunohistochemistry and real-time PCR. Claudins were rarely
observed exclusively at TJ structures. Claudin-1 was present in the
membrane of normal duct cells and in some of the cell membranes
fromductal carcinoma in situ, andwas frequently observed in eight out
of nine areas of apocrine metaplasia, whereas invasive tumors were
negative for claudin-1 or it was present in a scattered distribution
among such tumor cells (in 36/39 malignant tumors). Claudin-3 was
present in 49 of the 56 sections and claudin-4 was present in all 56
tissue sections. However, claudin-4 was highly positive in normal
epithelial cells and was decreased or absent in 17 out of 21 ductal
carcinoma grade 1, in special types of breast carcinoma (mucinous,
papillary, tubular) and in areas of apocrine metaplasia. Claudin-1
mRNA was downregulated by 12-fold in the tumor group. Claudins-3
and -4 mRNA exhibited no difference in expression between invasive
tumors and surrounding tissue. The signiﬁcant loss of claudin-1
protein in breast cancer cells suggests that this protein may play a role
in invasion andmetastasis. The loss of claudin-4 expression in areas of
apocrinemetaplasia and in themajority of grade 1 invasive carcinomas
also suggests a particular role for this protein in mammary glandular
cell differentiation and carcinogenesis.
Soini [57] also evaluated the expression of claudins-2, -3, -4, and -5
in 20 cases of Paget's disease (13 mammary and 7 extramammary
cases), and compared the results with those of other neoplastic skin
lesions, including actinic keratoses, basal cell carcinomas, and
malignant melanomas. Membrane-bound claudins-3 and -4 expres-
sion was seen in all cases of Paget's disease, whereas claudin-5 was
seen in 50% of cases and claudin-2 was seen in 32% of cases. However,
claudins-3, -4, and -5 were not seen in the other skin lesions, and
claudin 2 was seen in most of them, suggesting an inverse expression
of these claudins between Paget's disease and epidermal and
nevocytic lesions. Claudin expression in breast carcinomas was
claudin-2 in 52%, claudin-3 in 93%, claudin-4 in 92%, and claudin-5
in 47%. Claudins-2 and -5 were found more often in ductal carcinomas
than in lobular carcinomas. Expression of the claudins was frequently
associated with each other. They were not associated with estrogen or
progesterone receptor status or with tumor grade. No signiﬁcant
differences were found between claudin expression in Paget's disease
and breast carcinomas. The results demonstrate that claudins could be
useful in diagnosing Paget's disease and in differentiating these
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cell carcinomas, and nevocytic lesions. The lack of difference in
claudin expression between Paget's disease and breast tumors
suggests that changes in the phenotype of claudins-2, -3, -4, and -5
are not necessary for epidermal invasion.
Claudin-16 (paracellin-1), ponsin, ZO-2, AF6, vinculin andnectin are
reduced with poor prognosis of patients with breast cancer however
JAM-2 does not show differences in expression [58]. The levels of
transcripts of claudin-16 and vinculin were signiﬁcantly lower in
patients that had poor prognosis (with metastasis, recurrence or
mortality), compared with those that remained healthy after a median
follow-up of 72.2 months. Immunohistochemistry conﬁrmed these
results, as there was a decreased level in staining for claudin-16 and
AF6. In normal tissue, stainingwas conﬁned to the intercellular regions
whereas in the tumor tissues the stainingwas diffuse and cytosolic. The
conclusion was that low levels of TJ molecules claudin-16 and vinculin
in breast cancer are associated with poor prognosis in patients,
underscoring the idea that regulation of TJ could be of fundamental
importance in the prevention of metastasis of breast cancer cells.
Interestingly, the nectin family has been little studied as regards TJ
in cancer, being originally described as molecules involved in
adherens junctions only. Recently however, it has become apparent
that nectins are also involved in recruitment and maintenance of
proteins within the TJ [59]. Nectin-4was not detected in normal breast
epithelium. By contrast, nectin-4was expressed in 61% of ductal breast
carcinoma and in 6% in lobular type. Expression of nectin-4 strongly
correlated with the basal-like markers EGFR, P53, and P-cadherin, and
negatively correlatedwith the luminal-likemarkers ER, PR and GATA3.
All but one ER/PR-negative tumors expressed nectin-4. The detection
of nectin-4 in serum improves the follow-up of patients withMBC: the
association CEA/CA15.3/nectin-4 allowed to monitor 74% of these
patients compared to 67% with the association CEA/CA15.3. Serum
nectin-4 was a marker of disease progression, and levels correlate
with the number of metastases. Serum nectin-4 was also a marker of
therapeutic efﬁciency and correlated, in 90% of cases, with clinical
evolution. Nectin-4 appears to be a new tumor-associated antigen for
breast carcinoma and possibly new bio-marker whose use could help
reﬁne breast cancer taxonomy and improve patient follow-up. Nectin-
4 emerges as a potential target for breast cancer immunotherapy [59].
The claudins-1, -3, and -4 have been found to be differentially
expressed in the mammary gland during pregnancy, lactation, and
involution, suggesting different roles for these proteins at different
stages of mammary gland function [60]. In addition, claudins-1 and -3
are detected in mammary tumors and the wide distribution of
claudin-3 in particular, appears to suggest speciﬁc roles for these
proteins in mammary tumorigenesis.
Osanani et al. [61] had previously demonstrated that epigenetic
silencing of occludin resulted in the acquisition of apoptotic resistance
to various apoptogenic stimuli, causally contributing to the enhanced
tumorigenicity of cancer cells. In a recent study, the authors
demonstrated that forced expression of occludin induced anoikis
and promoted oxidative stress-induced premature senescence in
breast carcinoma cells, accompanied by upregulation of negative cell
cycle regulators such as p16INK4A, p21Waf1/Cip1 and p27Kip1 but
not p53. Endogenous re-expression of occludin mediated by a
synergistic effect with a demethylator and histone deacetylase
inhibitor or retinoids that stimulate retinoic acid receptor was also
sufﬁcient for provoking the senescent phenotype. In addition, tumors
developed from occludin-expressing cells in mice showed a feature of
cellular senescence that has not been described as a consequence of
occludin signalling. These ﬁndings suggested that the loss of occludin
expression could be partially involved in the senescence-escape
program during mammary tumorigenesis.
The Coxsackie-adenovirus receptor (CAR) is the primary site for
adenovirus attachment during infection and has been used as a
delivery mechanism for gene therapies. Martin et al. [62] evaluatedthe expression of CAR in human breast cancers. Staining intensity of
CAR was increased within tumor sections compared to background
tissue. Q-PCR revealed signiﬁcantly elevated levels of CAR transcript in
breast tumors. CAR expression also increased with grade of tumor.
Patients who had tumor metastases also showed elevated levels of
CAR expression, however those with local recurrences had reduced
levels of CAR. Ductal carcinomas expressed lower levels of CAR
compared to tumors of other types. Tumors with nodal involvement
were also associated with higher levels of CAR. Levels of CAR were
signiﬁcantly correlated with long-term survival over a period of
6 years. It appears that CAR expression is elevated in primary breast
cancers. This raises pertinent questions in two areas: could this
provide a key to treatment using viral vectors, or, does this elevated
expression result in dysregulation of barrier function? Further
research is required to uncover these questions.
6.1.2. Peripheral plaque proteins in breast cancer
MAGUKs may play a vital role in cellular functions preventing
tumorigenesis as indicated by neoplastic phenotypes in Drosophila;
Normal breast tissues have shown the expected intense staining at
cell–cell junctions; however, ZO-1 staining is found to be reduced or
lost in 69% of breast cancers analyzed using immunohistochemistry
[20]. Normal tissue showed intense staining for ZO-1 at the position of
the epithelial TJ, but this was lost or reduced in 69% of breast cancers
analyzed. In inﬁltrating ductal carcinomas there was a reduction in
staining in 42% of well differentiated, in 83% of moderately
differentiated and in 93% of poorly differentiated tumors. ZO-1 was
positively correlated with tumor differentiation, and more speciﬁcally
with the glandular differentiation of tumors. The ZO-1 gene tjp-1was
mapped relative to other markers ﬂanking the gene. There was a loss
of heterozygosity in 23% of informative tumors. Loss of a tjp-1-linked
marker suggests that genetic loss may, in some cases, be responsible
for a reduction in ZO-1 in breast cancer.
ZO-2 can be expressed in two isoforms, ZO-2A and ZO-2C, in
normal epithelia. ZO-2A is absent in pancreatic adenocarcinoma of the
ductal type, with none of the common mechanisms of gene
inactivation responsible [21]. Analysis of the ZO-2 promoters (PA
and PC) showed that lack of expression of ZO-A in neoplastic
pancreatic cells is caused by inactivation of the downstream promoter
PA, probably due to structural or functional alterations in the
regulatory elements localized outside the analyzed promoter region
as hypermethylation was not a convincing reason in early cancers.
However, methylation of PA is responsible for the inactivation of the
suppressed promoter at the late stages of tumor development [33].
ZO-2 was found to be de-regulated in breast adenocarcinoma, but not
in colon or prostate adenocarcinoma, both of which are considered to
be of acinar rather than ductal type. Also, in 18 breast cancer cell lines,
the most poorly-differentiated, ﬁbroblastic cell lines were ZO-1
negative, and were highly invasive [63].
Martin et al. [24] investigated the expression of ZO-1, ZO-2 and ZO-
3, and MUPP-1 in patients with primary breast cancer (Fig. 3).
Standardised transcript levels of ZO-1 and MUPP-1 were signiﬁcantly
lower in patients with metastatic disease compared with those
remaining disease-free (median follow-up 72.2 months). Immuno-
histochemistry conﬁrmed these results, with decreased levels in ZO-1
staining. For both ZO-1 and ZO-3, staining was conﬁned to the
intercellular regions in normal tissue, whereas in tumor tissues
staining was diffuse and cytosolic. Q-PCR revealed a reduction in the
levels of ZO-1 and MUPP-1 in patients with disease recurrence.
Prognostic indicators of breast cancer were also inversely correlated
with ZO-1 expression. It was concluded that low levels of TJ plaque
molecules, such as ZO-1 and MUPP-1 in breast cancer are associated
with poor patient prognosis.
ZO-1 is able to upregulate HER-2/neu expression in vitro by
sequestering a repressor of the Her-2/neu gene promoter [22]. ZO-1
expression was examined in a series of breast cancers: one group
Fig. 3. Panel shows the differential expression of peripheral/plaque proteins in representative sections from patients with breast cancer. (A) Immunohistochemical staining (X100) of
ZO-1, -2 and -3 in human breast cancer tissues. Clear staining is shown in normal tissue (left), reduced staining for ZO-1 and -3 shown in the right. (B) Western blotting of paired
normal and tumor tissues and densimetric analysis.
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was analyzed by IHC: ZO-1 expression did not correlate with HER-2/
neu expression in breast carcinomas, and so other causes of HER-2/neu overexpression should be sought. Interestingly, the authors report
that ZO-1 IHC stained DCIS were positive for ZO-1 in 18/20 cases, with
4/18 negative for ZO-1 in the invasive tumor.
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is characterized by the loss of cell–cell adhesion contacts and the
expression of degradative properties. Polette et al. [64] examined the
effect of the disorganization of occludin/ZO-1 complexes on the
expression of membrane-type 1 matrix metalloproteinase (MT1-
MMP). The expression of MT1-MMP in invasive breast tumor cell lines
correlated with the absence of occludin and with a cytoplasmic
localization of ZO-1. In contrast, non-invasive cell lines displayed a
membrane staining for both ZO-1 and occludin and did not express
MT1-MMP. Cytoplasmic ZO-1 and MT1-MMP could be detected in
invasive tumor clusters of human breast carcinomas. ZO-1 small
interfering RNA transfection down-regulated MT1-MMP mRNAs and
proteins and subsequently decreased the ability of tumor cells to
invade. The authors conclude that ZO-1 can intervene in signalling
events promoting tumor cell invasion. It is apparent that not only is
down-regulation of TJ proteins important in effecting an invasive
phenotype, but that intracellular mislocalization can be just as
important: if the TJ protein in question has not been targeted
correctly, the structure and function of the TJ will be impaired.
6.2. Bladder cancer
6.2.1. Transmembrane proteins in bladder cancer
Recently, interest in the role of TJ in bladder carcinoma has
increased. A timely review explored the current understanding on the
role and regulation of TJ function in the normal and diseased bladder
[65]; however, few studies have materialised to further interest in this
area. Boireau et al. [66] analyzed the expression and localization of
claudins-1, -4, and -7 in human bladder carcinoma. Claudin-4
expression was signiﬁcantly altered in 26/39 tumors, contrasting
with the rare modiﬁcations detected in the expression of claudins 1
and 7. Overexpression of claudin-4 in differentiated carcinomas was
followed by a strong downregulation in invasive/high-grade tumors,
and this expression pattern was associated to the 1-year survival of
bladder tumor patients. A CpG island was identiﬁed within the coding
sequence of the claudin-4 gene, and treatment with a methyl-
transferase inhibitor restored expression of the protein in primary
cultures prepared from high-grade human bladder tumors. Claudin-4
expression also correlated with its gene methylation proﬁle in healthy
and tumoral bladders from 20 patients. Delocalization of claudins-1
and -4 from TJ was observed inmost human bladder tumors and in the
bladder tumor cell line HT-1376. Although the claudin-4 gene was
unmethylated in these cells, inhibition of methyl transferases re-
addressed the two proteins to TJ, resulting in an increase of cell
polarization and transepithelial resistance. These biological effects
were prevented by expression of claudin-4-speciﬁc siRNAs, demon-
strating the important role played by claudin-4 in maintaining a
functional regulation of homeostasis in urothelial cells. The authors
concluded that the TJ barrier is disrupted from early stages of
urothelial tumorigenesis and that hypermethylation was the leading
to the alteration of claudin-4 expression and localization in bladder
carcinoma.
6.3. Colorectal cancer
6.3.1. Transmembrane proteins in colorectal cancer
Since Soler et al. [45] revealed the TJ of colon tumors – both natural
and induced – were “leakier” than those of normal colon there have
been a number of studies looking at colorectal carrier function. It has
been demonstrated that there is an inverse relationship between the
expression of claudin-1 and Smad4, a tumor suppressor protein, in
colon cancer cell lines and in human colon cancer tissue samples [67].
Smad4 expression in Smad4-deﬁcient colon cancer cells inhibited
claudin-1 expression through transcriptional regulation. Further
analysis suggested the important role of h-catenin/T-cell factor
(TCF)/lymphocyte enhancer factor (Lef) activity in the Smad4-dependent regulation of claudin-1 expression. In addition, the
inhibition of claudin-1 expression contributes to the ability of
Smad4 to inhibit invasion in colon cancer cells. Smad4-dependent
inhibition of claudin-1 expression was a direct effect of Smad4
expression and not due to modulation of TGF-h signalling. Resnick et
al. [14] investigated the pattern of expression and prognostic value of
claudin-1, claudin-4, occludin and ZO-1 in a cohort of TNM stage II
colon cancer using tissue microarray technology and retrospectively
analyzed samples form 129 patients with TNM stage II colonic
carcinomas for claudin-1, claudin-4, occludin and ZO-1 protein
expression by immunohistochemistry. Seventy-ﬁve, 58, 56 and 44%
of the tumors exhibited normal to elevated expression levels of
claudin-1, claudin-4, occludin and ZO-1 respectively. Low expression
levels of claudin-1 and ZO-1 were directly associated with higher
tumor grade. Multivariate analysis indicated that lymphovascular
invasion and low levels of claudin-1 expression were independent
predictors of recurrence and that reduced claudin-1 expression was
associated with poor survival. This was the ﬁrst study to comprehen-
sively examine the expression of several TJ associated proteins in
colonic neoplasms and to correlate their expression with disease
progression. Loss of claudin-1 expression proved to be a strong
predictor of disease recurrence and poor patient survival in stage II
colon cancer.
A more recent study looked at the expression analysis of genes
encoding TJ proteins to display differential gene expression on RNA
and protein level and to identify and validate potential targets for
colorectal cancer therapy [68]. Claudins-1 and -12 are frequently over-
expressed in colorectal cancer, whereas claudin-8 showed down-
regulation in tumor tissue at the RNA level. Quantiﬁcation of proteins
conﬁrmed the overexpression of claudin-1 in tumor tissues, whereas
changes of claudins-8 and -12 were not signiﬁcantly detectable on
protein level. IHC conﬁrmed the markedly elevated expression level of
claudin-1 in the majority of colorectal cancer, showing membranous
and intracellular vesicular staining. The authors concluded that
differential expression of genes encoding claudins in colorectal cancer
suggests that these TJ proteins may be associated to and involved in
tumorigenesis. As claudin-1 is frequently up-regulated in large
proportion of colorectal cancers and may represent potential target
molecule. Added to their intrinsic properties in a correctly functioning
TJ, it is becoming apparent that the over-expression of absence of
expression of these proteins might provide evidence of prognostic
value. In adenocarcinoma tissues the expression of claudins-1, -3 and -
4 has been found to be upregulated [69]. Tokunaga et al. [70]
investigated whether or not occludin is expressed in rosette or gland-
like structures in human rectal carcinoid tumors. The expression
proﬁles of occludin in 40 carcinoid tumors were examined immuno-
histochemically, using an anti-occludin monoclonal antibody. In eight
(20%) samples of typical carcinoid tumors, a small number of rosette-
like tubular structures outlined by occludin were detected. Thus
occludin might be considered to be one of the most characteristic
structural markers of polarized glandular structures. The results of this
study provided supportive evidence that carcinoid tumor cells are
capable of glandular differentiation. The signiﬁcance of claudin-4
expression in colorectal cancer and its association with clinicopatho-
logical factors was examined [71]. The levels of claudin-4 expression
in a total of 129 colorectal cancers and 44 metastatic tumors were
examined by immunohistochemistry. A small interfering RNA
(siRNA)-mediated claudin-4 knockdown examination was also con-
ducted to assess the biological role(s) of claudin-4 in cultured cells.
Expression of claudin-4 at the intercellular membrane was well
preserved at the surface of tumors, with decreased claudin-4
expression detected in colorectal cancers, particularly at the invasive
front. Interestingly, decreased claudin-4 expression was detected in
metastatic lesions of colorectal cancer. siRNA-mediated claudin-4
knockdown in SW480 claudin-4-positive colorectal cancer cells
upregulated cell motility, whereas no signiﬁcant change was detected
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enhances cancer cell invasion and metastasis in human colorectal
cancer and claudin-4 might be a good biomarker for diagnosing the
risk of distant metastasis. It is interesting to note that the claudin-1
gene is regulated by β-catenin [72]. Expression of claudin-1 decreases
signiﬁcantly in response to reduction of intracellular β-catenin by
adenovirus-mediated transfer of wild-type APC into the APC-deﬁcient
colon cancer cells, with two putative Tcf4 binding elements in the 5′
ﬂanking region of claudin-1 being responsible for activating its
transcription. The authors again demonstrate increased expression
of claudin-1 in primary colorectal cancers. Furthermore, immunohis-
tochemical staining demonstrated that claudin-1 was weakly stained
at apical boarder of lateral membrane of noncancerous epithelial cells
and that it was strongly stained at all cell–cell boundaries and in the
cytoplasms of cancer cells. Such results imply that claudin-1 is
involved in the beta-catenin-Tcf/LEF signalling pathway. Moreover, it
has been reported that there is an increased expression of claudin-1 in
human primary colon carcinoma and metastasis and in cell lines
derived from primary and metastatic tumors [73]. There was frequent
nuclear localization of claudin-1 in these samples. Genetic manipula-
tions of claudin-1 expression in colon cancer cell lines induced
changes in cellular phenotype, with structural and functional changes
in markers of epithelial–mesenchymal transition. It was also demon-
strated that changes in claudin-1 expression had signiﬁcant effects on
growth of xenografted tumors and metastasis in athymic mice. Data
suggests that the regulation of E-cadherin expression and β-catenin/
Tcf signalling is a possible mechanism underlying claudin-1-depen-
dent changes. Kinugasa et al. [74] also state that claudin-1 and
claudin-2 were found to be over-expressed in colorectal cancer
tissues. They may be useful as tumor markers and targets for the
treatment of colorectal cancer.
6.3.2. Peripheral plaque proteins in colorectal cancers
Tubular gland structures of colorectal cancer have been demon-
strated to undergo dedifferentiation at the primary site, with the
gland structures re-formed in liver metastases. Kaihara et al. [75]
examined the degree of differentiation of the gland structure of 48
cases of colorectal cancers (24 cases with synchronous liver
metastasis, 24 cases without metastasis) by the modiﬁed Gleason
grading system. The role of ZO-1, in the morphological changes
(dedifferentiation and redifferentiation) at the primary site and liver
metastases was also looked at. Liver-metastasized colorectal cancers
showed a lower score in the modiﬁed Gleason grading system than
the corresponding primary tumors. The tumor cells had undergone
redifferentiation at liver metastases. ZO-1 was expressed at the apical
cell borders of normal colorectal epithelium, the luminal side of which
has tubular gland structures. In comparison with this normal
epithelium, the ZO-1 expression level was frequently reduced in
primary colorectal cancer with liver metastasis (20.8%) and ZO-1 was
re-expressed in liver metastasized cancers (79.2%). Immunoprecipita-
tion of colorectal cancers with liver metastasis showed that ZO-1
bound to epidermal growth factor receptor (EGFR) irrespective of the
phosphorylation status of EGFR, and that EGFR associated ZO-1 was
highly tyrosine-phosphorylated only in the primary colorectal
cancers, but was dephosphorylated in the liver-metastasized cancers.
The authors suggest that tyrosine phosphorylation of ZO-1 leads to
down-regulation of the function of ZO-1 and dedifferentiation of the
glands in colorectal cancers, and these phenomena contribute to liver
metastases, and redifferentiation of the glands occurs in the liver
metastases.
6.4. Eesophageal cancer
6.4.1. Transmembrane proteins in esophageal cancer
The majority of studies on TJ in esophageal cancer have
concentrated on transmembrane proteins in the claudin family. Thisis also reﬂected by the growing number of studies indicating the
importance of TJ function in the precancerous predecessor to
esophageal cancer, Barrett's esophagus. Recently, Miyamoto et al.
[76] examined 54 esophageal cancer cases to assess immunohisto-
chemical expression patterns of claudin-1 with decreased expression
of claudin-1 being statistically correlated with recurrence status.
Decreased expression of claudin-1 was also correlated with short
disease-free and overall. The results suggest that claudin-1 expression
is correlated with the recurrence status and poor prognosis in
esophageal cancer and claudin-1 expression may be a good indicator
of recurrence in esophageal cancer.
Upregulation of claudins 3, 4, and 7 was identiﬁed in gastric
adenocarcinomaMontgomery et al. [77].While normal gastricmucosa
lacked claudin 3, 4, and 7 expression, intestinal metaplasia and
dysplasia showed these proteins. The authors hypothesized that
claudins would be similarly overexpressed in Barrett's esophagus (BE)
adenocarcinoma. The ﬁndings suggest that alterations in claudin
proteins are an early event in tumorigenesis and may provide targets
for diagnosis and directed therapy for esophageal adenocarcinoma
and its precursors. Earlier studies [78] showed that reduced expres-
sion of claudin-7 at the invasive front of the esophageal cancer was
signiﬁcantly associated with the depth of invasion, lymphatic vessel
invasion and lymph node metastasis. In contrast, signiﬁcant associa-
tion was not detected between claudin-1 expression and clinico-
pathologic factors except for histologic differentiation of the tumor.
Claudin-7 expression at the invasive front of the primary tumor and its
corresponding metastatic lymph nodes revealed signiﬁcant reduction
in claudin-7 expression in the metastatic lymph nodes suggesting that
the reduced expression of claudin-7 at the invasive front of esophageal
squamous cell carcinoma may lead to tumor progression and
subsequent metastatic events. Moreover, Lioni et al. [79] examine
the expression of claudin-7 in squamous cell carcinoma (SCC) of the
esophagus and its possible role in tumor progression. In this context,
the claudin-7-overexpressing cells became more adhesive and less
invasive associated with increased E-cadherin expression. Claudin-7
was mislocalized during the malignant transformation of esophageal
keratinocytes. This demonstrated that there might be a critical role for
claudin-7 expression in the regulation of E-cadherin in these cells,
suggesting that this may be one mechanism for the loss of epithelial
architecture and invasion observed in esophageal SCC.
Patients with Barrett's [80] were observed to exhibit a transe-
pithelial leak to sucrose whose mean value was threefold greater than
that seen in healthy control subjects or patients with reﬂux but
without any mucosal defect. A parallel study of claudin tight junction
proteins in endoscopy biopsy samples showed that whereas Barrett's
metaplasia contains dramatically more claudin-2 and claudin-3 than
is found in normal esophageal mucosa, it is markedly lower in
claudins 1 and 5, indicating very different tight junction barriers. A
later study of 21 claudins in Barrett's oesophagus [81] (BE) and
specialized columnar epithelium (SCE) that develops as replacement
for damaged squamous epithelium (SqE) in subjects with reﬂux
disease, demonstrated that in SCE, claudin-18 was the most highly
expressed at the mRNA level and this ﬁnding is paralleled by marked
elevation in protein expression on immunoblots. In contrast in SqE,
claudin-18 was minimally expressed at the mRNA level and
undetectable at the protein level. Immunoﬂuorescence studies
showed membrane localization of claudin-18 and colocalization
with ZO-1. This prompted the authors to conclude that claudin-18 is
the dominant claudin in the TJ of SCE and propose that the change
from a claudin-18-deﬁcient TJ in SqE to a claudin-18-rich TJ in SCE
contributes to the greater acid resistance of BE. An early study by
Rendon-Huerta et al. [82] observed that occludin is in fact found in
normal esophageal tissue, in contrast to an earlier publication
reporting its absence in esophagus [82]. They also observed that the
amounts of occludin on a per-mg-total-protein basis are not different
for biopsies from Barrett's metaplasia compared with adjacent normal
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claudins with claudin-1 being fairly abundant in normal esophagus
but is absent in some Barrett's metaplasia biopsies and sharply
reduced in most others. Claudin-2 presented a somewhat opposite
picture, that is, consistently nondetectable in normal esophageal
epithelium but detectable at low-to-moderate levels in two of eight
Barrett's biopsies.
6.4.2. Peripheral plaque proteins in esophageal cancer
Kimura et al. [83] investigated occludin expression in conjunction
with ZO-1 in normal epithelia and cancers of human digestive tract.
ZO-1 was expressed as a single line at the apical cell border. In the
esophagus ZO-1was expressed in the spinous layer. As for tumors, ZO-
1 showed the same expression in differentiated adenocarcinoma cells
as in normal epithelium, but in poorly differentiated adenocarcino-
mas, the expression was reduced. There was a signiﬁcant correlation
between tumor differentiation and expression of these proteins. It was
posited that ZO-1 could be involved in the formation of gland-like
structures.
6.5. Gastric cancer
6.5.1. Transmembrane proteins in gastric cancer
Disruption of the TJ observed in the study by Fedwick et al. [46]
implicates host cell signalling pathways, including the phosphoryla-
tion of myosin light chain and the regulation of tight-junctional
proteins claudin-4 and claudin-5, in the pathogenesis of Helicobacter
pylori infection. As gastric carcinoma remains one of most serious
malignant tumors worldwide with Helicobacter pylori being the
deﬁnite carcinogen this is an interesting area in determining the
role of TJ barrier function [84]. The Helicobacter pylori components,
cytotoxin-associated gene A (CagA), vacuolating toxin A (VacA) and
blood-group antigen-binding adhesin gene (BabA), can mimic and
bind to speciﬁc receptors or surface molecules both on gastric
epithelial cells and platelets, in which CagA and VacA may also be
directly involved in loosening of TJ in monolayers of polarized gastric
epithelial cells. It has been shown that a history of Helicobacter pylori
infection is found in the majority of patients with GC, and that anti-
CagA, anti-VacA and anti-BabA antibodies targeting both Helicobacter
pylori components and host mimic molecules can be detected in them
with increased levels. Patients with GC who are positive for Helico-
bacter pylori prospectively have a better outlook than those negative.
The stimulation of mentioned autoantibodies in antigen processing
and presentation and subsequent T-cell activation and proliferation
improves host immune status. On the other hand, in an autoimmune
response, autoantibodies can induce the cross-reaction against those
localized or circulating GC cells, which are characterized by mimic or
absorbed Helicobacter pylori antigens, and lead to the killing and even
suppressing of metastasis of cancer cells [84].
In the poorly differentiated gastric cancer cell line TMK-1, ZO-1 and
occludin have been shown to be predominantly localized to the
cytoplasm, although there is some weak expression at the cell–cell
contact [85]. Epidermal growth factor (EGF), a growth factor that is
often overexpressed in gastric cancer causes ZO-1 and occludin to be
rapidly translocated from the cytosol to the cell–cell contact. These
effects induced by EGF were attenuated in the presence of protein
kinase C (PKC) inhibitors calphostin C and bisindolylmaleimide I, but
not another PKC inhibitor Gö6976, PD98059 (MAPK inhibitor),
LY294002 (PI3 kinase inhibitor) or KT5720 (protein kinase A
inhibitor). Yoshida et al. [85] suggest that EGF can rapidly alter the
localization of ZO-1 and occludin via a protein kinase C signalling
pathway in TMK-1 gastric cancer cells. In situ hybridization was used
to evaluate the expression of occludin mRNA in 42 gastric carcinoma
specimens obtained by surgery and 23 relatively normal gastric
mucosa obtained by gastric endoscopy [86]. Occludin mRNA was
found positive in the cytoplasm of gastric glandulous epithelia as blueparticleswith intensive stain in 14 of 42 gastric carcinomas (33.3%), 23
of 42 paracancerous gastric tissues (54.8%), 14 of 23 relatively normal
gastric tissues (60.9%), 9 of 16 well differentiated carcinomas (56.3%),
4 of 14 moderately differentiated carcinomas (28.6%), 1 of 10 poorly
differentiated carcinomas (10.0%) and none of 2 mucosal carcinomas.
There were signiﬁcant differences in occludin mRNA positive rate
between relatively normal gastric tissue and gastric cancer as well as
between paracancerous gastric tissue and gastric cancer. The expres-
sion of occludinmRNA inmoderately and poorly differentiated groups
was gradually reduced when compared with well differentiated
group, which suggests that there be a signiﬁcant correlation between
tumor differentiation and the expression of occludin mRNA. Further-
more, the positive signals of occludin mRNA distributed extensively in
the cytoplasm of SGC7901/VCR cell, being vincristine resistant,
derived from parental gastric cell line SGC7901. The positive signals
of SGC7901/VCR were stronger than those of SGC7901 cells. The
authors suggest that occludin mRNA, being mainly located in
epithelial cells and its expression correlated with tumor differentia-
tion, may be involved in the development of multi-drug resistance in
gastric cancer.
A new claudin-based gastric cancer classiﬁcation system for gastric
cancer has been proposed [87]. The authors examined the expression
of gastric (claudin-18) and intestinal (claudin-3 and claudin-4)
claudins in non-neoplastic gastric mucosa (with intestinal metaplasia
[IM], 78 cases; without IM, 88 cases) and 94 gastric cancers was
analyzed immunohistochemically, as was the expression of gastric
(MUC5A and MUC6) and intestinal (CD10 and MUC2) mucins.
Heterogeneous expression of claudin-3, claudin-4 and claudin-18
was detected in advanced gastric cancer; however, there was no
signiﬁcant association between the claudins and the clinicopatholo-
gical parameters. These gastric cancer tissues were also sub classiﬁed
into claudin-based phenotypes: gastric claudin, 28 cases (30%);
intestinal claudin, 41 cases (44%); and unclassiﬁed claudin, 25 cases
(26%). Interestingly, the gastric cancers with unclassiﬁed claudin had
worse malignancy grades, not only in size and invasiveness but also in
potential metastatic ability and patient outcome. Although the mucin-
based gastric cancer classiﬁcation was also assessed, no signiﬁcant
correlation was found between mucin production and clinicopatho-
logical parameters. These observations suggest that loss of claudin
expression may enhance the grade of malignancy of gastric cancer in
vivo. Classiﬁcation of gastric cancers using gastric and intestinal
claudins is a good biomarker for assessing the risk of poor prognosis.
Quantitative real-time reverse transcriptase-polymerase chain reac-
tion and immunohistochemistry have shown that claudin-7 is over-
expressed in 10 Tff1−/− gastric dysplasia samples [88]. Comparison
with a serial analysis of gene expression database of human gastric
cancer revealed similar deregulation in human gastric cancers.
Quantitative real-time reverse transcriptase-polymerase chain reac-
tion of human gastric adenocarcinoma samples indicated that, of
these three genes, claudin-7 was the most frequently up-regulated
gene. Using immunohistochemistry, both mouse and human gastric
glands overexpressed claudin-7 in dysplastic but not surrounding
normal glands. Claudin-7 expression was observed in 30% of
metaplasia, 80% of dysplasia, and 70% of gastric adenocarcinomas.
Interestingly, 82% of human intestinal-type gastric adenocarcinomas
expressed claudin-7 whereas diffuse-type gastric adenocarcinomas
did not. These results suggest that claudin-7 expression is an early
event in gastric tumorigenesis that is maintained throughout tumor
progression [88]. Kuo et al. [89] continued to explore the roles of
claudin-4 in the two histologically distinct types of gastric cancer; we
selected 45 IGC (intestinal-type gastric cancer) and 48 DGC (diffuse-
type gastric cancer) cases and then analyzed the expression of the
protein using immunohistochemistry. The authors discovered that the
overexpression of claudin-4 was greater in IGC than in DGC. A trend
was observed between the overexpression of claudin-4 and lymph
node metastasis, however, this association was not statistically
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lower in DGC. Possibly it played a role in determining the diffuse
phenotype and loose cohesion of cells in DGC in a similar manner as
E-cadherin.
Resnick et al. [90] determined the expression pattern of claudins-1,
-3, and -4 as well as ZO-1 in large series patients with gastric cancer
and to correlate expression with clinicopathologic and prognostic
variables. Tissue microarrays were created from parafﬁnized samples
from 146 patients with distal gastric adenocarcinomas (61 intestinal
and 85 diffuse or mixed subtypes). In addition, cores of normal
mucosa and intestinal metaplasia were taken from most cases. The
microarrays were stained for claudins 1, 3, and 4 and ZO-1, and the
intensity of staining was determined using a 3-point scale. Moderate
claudin 1 and ZO-1 membranous staining were present, whereas only
focal weak claudins 3 and 4 membranous staining was present in
normal gastric epithelium.Moderate to strong staining of claudins 1, 3,
4, and ZO-1 was disparate in intensity. Cox multivariate analysis
revealed that tumor stage, diffuse subtype, and moderate to strong
claudin 4 staining were associated with decreased survival. The
authors state that these TJ proteins were strongly expressed in most
gastric intestinal-type adenocarcinomas but less frequently in diffuse
gastric cancers. The up-regulation of claudin expression during gastric
carcinogenesis suggests their potential utility as diagnostic biomar-
kers and possible targets for therapeutic intervention.
Park et al. [91] demonstrated that claudin-7 was up-regulated in
gastric carcinoma. Claudin-7 was signiﬁcantly more often expressed
in intestinal metaplasia, adenoma and cancer than in normal gastric
epithelium. Claudin-7 was more often unexpressed in diffuse type
gastric cancer than in intestinal type. Compared to normal gastric
epithelium, intestinal type gastric cancer signiﬁcantly more often
expressed claudin-7, but diffuse type did not. The expression pattern
of claudin-7 did not change as cancer progressed. In this study we
show that claudin-7 expression changed with the gastric carcinogenic
process and that this is implicated in cancer characteristics.
6.5.2. Peripheral plaque proteins in gastric cancer
Similar patterns of expression have been noted for E-cadherin and
claudin-4, but ZO-1 expression differed in gastric cancer tissues [92].
According to the Lauren classiﬁcation, the reduced expression of E-
cadherin and claudin-4 was more frequent in diffuse than intestinal
type tumors with the reduced expression of E-cadherin and claudin-4
correlated with poor differentiation.Western blot analysis and RT-PCR
also showed decreased claudin-4 expression in diffuse type tumors
and poorly-differentiated adenocarcinoma. The reduced expression of
claudin-4 and E-cadherin correlates with disruption of glandular
structure and loss of differentiation, which suggests that the
dysfunction of claudin-4 may play a role in the disruption of cell-to-
cell adhesion in diffuse type gastric cancer and in a loss of
differentiation.
6.6. Gynaecological cancers
6.6.1. Transmembrane proteins in gynaecological cancers
Cell–cell and cell–extracellular matrix interaction is crucial in
tumor progression [93]. The expression of occludin and claudins (and
syndecan-1) in early stage cervical carcinogenesis showed that
occludin and claudin-2 were found colocalized in the basal layer,
while syndecan-1 and claudins-1, -4 and -7 were coexpressed in the
parabasal and intermediary layers in normal epithelia. Intensity of
occludin staining decreased in CIN/CIS lesions, although it was more
extended towards the upper epithelial layers with inverse relation
with grades, as seen in the case of claudin-2 expression. Claudins-1, -2,
-4 and -7 were detected in the entire epithelium in CIN, showing
decrease in CIS. The progression of CIN was associated with reduced
syndecan-1 expression, in contrast to claudins-1, -4 and -7 which
increased toward CIS. It is thought that signiﬁcant changes occur inthe composition of cell adhesion complexes even in early stages of
cervical carcinogenesis [92]. In ovarian cancer, laboratory generated
human ovarian surface epithelial (HOSE) cells constitutively expres-
sing wild-type claudin-3 and claudin-4 [94]. Expression of these
claudins in HOSE cells increased cell invasion andmotility. Conversely,
knockdown of claudin-3 and claudin-4 expression in ovarian cancer
cell lines reduced invasion. Claudin expression also increased cell
survival in HOSE cells but did not signiﬁcantly affect cell proliferation.
Moreover, the claudin-expressing ovarian epithelial cells were found
to have increased matrix metalloproteinase-2 (MMP-2) activity
indicating that claudin-mediated increased invasion might be
mediated through the activation of MMP proteins. siRNA inactivation
of claudins in ovarian cancer cell lines did not have a signiﬁcant effect
on the high endogenous MMP-2 activity present in these cells. This
could be construed as malignant cells having alternative or additional
pathways to fully activate MMP-2 and suggests that claudin over-
expression may promote ovarian tumorigenesis and metastasis due to
increased invasion and survival of tumor cells.
Claudin-7 has been found to have highly differential expression in
ovarian carcinoma [95]. 110 patients with various histologic types of
epithelial ovarian carcinomas were studies, with claudin-7 transcript
found signiﬁcantly overexpressed in both primary and metastatic
tumors compared to normal human ovarian surface epithelium cell
lines. At the protein level, claudin-7 expressionwas found signiﬁcantly
higher in tumors of primary and metastatic origin when compared to
normal ovaries, regardless of the histologic type, the grade of
differentiation, and the pathologic stage of the disease. Claudin-7
was thus found to be signiﬁcantly overexpressed in all main histologic
types of epithelial ovarian cancer and in single neoplastic cells
disseminated in peritoneal cavity and pleural effusions, suggesting its
potential role as novel diagnostic marker in ovarian cancer. Claudin-4
is also overexpressed in epithelial ovarian cancer [96]. Claudin-4
overexpression in did not correlate with survival or other clinical
endpoints and is associated with hypomethylation. Claudin-4 over-
expression did correlate changes in barrier function by treatment with
the Clostridium perfringens enterotoxin in a dose- and claudin-4-
dependent noncytotoxic manner. There is a weak or absence of
expression of claudin-3 and claudin-4 in surface human ovarian
surface epithelium changed to typical cell-border localization with of
inclusion cysts in the normal ovarian stroma [97]. Semiquantitative
estimations of immunoblots showed that claudin-3 was signiﬁcantly
increased in ovarian adenocarcinomas compared to benign and
borderline-type tumors. Claudin-4 was signiﬁcantly increased in
both borderline-type and ovarian adenocarcinomas compared to
benign tumors, whereas no changes were found for claudin-1 or -5.
Claudin-3, but not claudin-4, was signiﬁcantly increased in moder-
ately, poorly and undifferentiated adenocarcinomas compared to well
differentiated and borderline-type tumors (FIGO grade). The authors
concluded that both claudins-3 and -4, even though they differ in
expression during ovarianmalignant transformation, might be used as
novel markers for ovarian tumors. A small region of the claudin-4
promoter is critical for its expression [98]. This region contains two
Sp1 sites required for promoter activity. However, because of the
ubiquitous expression of Sp1, these sites, although necessary, are not
sufﬁcient to explain the patterns of gene expression of claudin-4 in
various ovarian tissues. The claudin-4 promoter was found to be
further controlled by epigenetic modiﬁcations of the Sp1-containing
critical promoter region. Cells overexpressing claudin-4 exhibit low
DNA methylation. The authors conclude that as claudin-4 is elevated
in a large fraction of ovarian cancer, the mechanism leading to
deregulation may represent a general pathway in ovarian tumorigen-
esis and may lead to novel strategies for therapy and an overall better
understanding of the biology of this disease [98]. D'Souza et al. [99]
showed that claudins-3 and -4 can be phosphorylated in ovarian
cancer cells, suggesting that claudin-3 phosphorylation by PKA, a
kinase frequently activated in ovarian cancer, may provide a
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general implications for the regulation of TJ in normal epithelial cells.
In ovarian cell lines, ET-1 (ETAR)/endothelin-1 axis (ET-1) induces
loss of adherens and tight-junction protein expression, E-cadherin, b-
catenin, and ZO-1, and gain of N-cadherin and vimentin expression
[100].
Normal endometrial glands and samples of endometrial hyper-
plasia and endometrioid carcinoma grade 1 fully expressed occludin
at the apical cell border [101]. In endometrioid carcinomas grades 2
and 3, however, occludin disappeared in solid areas of the
carcinomatous tissues. Occludin was also found at the apical borders
of the cancer cells that formed glandular structures. Occludin
expression decreased progressively in parallel with the increase in
carcinoma grade, and the decreased occludin expression correlated
with myometrial invasion and lymph node metastasis. These results
suggest that the loss of TJ has a close relationship with structural
atypia in the progression of human endometrial carcinomas and their
malignant potential [102].
6.7. Prostate cancer
6.7.1. Transmembrane proteins in prostate cancer
Long et al. [102] investigated the expression of claudin-3 and
claudin-4 in human prostate tissue as potential targets for CPE toxin-
mediated therapy for prostate cancer. On human multiple-tissue
Northern blot analysis, mRNAs for both claudin-3 and claudin-4 were
expressed at high levels in prostate tissue. In normal prostate tissue,
expression of claudin-3 was localized exclusively within acinar
epithelial cells by in situ mRNA hybridization. Compared with
expression within prostate epithelial cells in surrounding normal
glandular tissue, expression of claudin-3 mRNA remained high in the
epithelium of prostate adenocarcinoma (10 of 10) and prostatic
intraepithelial neoplasia (5 of 5). Prostate adenocarcinoma cells
metastatic to bone were obtained from a patient with disease
progression during anti-androgen therapy. These metastatic cells
were prostate-speciﬁc antigen-positive by immunohistochemical
staining and also expressed functional CPE receptors. The persistent
high level of claudin-3 expression in prostate adenocarcinoma and
functional cytotoxicity of CPE in metastatic androgen-independent
prostate adenocarcinoma suggests a new potential therapeutic
strategy for prostate cancer.
Zheng et al. [103] described two forms of claudin-7, a full length
form of with 211 amino-acid residues and a C-terminal truncated form
with 158 amino-acid residues. These two forms of are able to regulate
the expression of a tissue-speciﬁc protein, the prostate-speciﬁc
antigen (PSA), in the LNCaP prostate cancer cell line. The authors
also found that the expression of claudin-7 was responsive to
androgen stimulation in the LNCaP cell line, suggesting that this
protein is involved in the regulatory mechanism of androgen. Both
forms of claudin-7 were expressed in human prostate, kidney and
lung samples, and in most samples, the full-length form of claudin-7
was predominant. However, in some prostate samples from healthy
individuals, the truncated form of claudin-7 is predominantly
expressed. It appeared that unlike other claudins, claudin-7 has both
structural and regulatory functions, and the two forms of claudin-7
may be related to cell differentiation in organ development.
There is only one reported study documenting the pattern of
claudin expression in prostatic adenocarcinomas [104]. Decreased
expression of claudin-1 correlated with high tumor grade and
biochemical disease recurrence, whereas decreased claudin-7 corre-
lated with high tumor grade. In contrast, expression of claudin-3
correlated with advanced stage tumors and recurrence and expression
of claudin-4 correlated with advanced stage. On multivariate analysis,
advanced stage and decreased claudin-1 protein expression indepen-
dently predicted disease recurrence. The authors conclude that
immunohistochemical expression and prognostic signiﬁcance ofclaudins are variable in prostatic adenocarcinomas, with decreased
expression of claudin-1 emerging as an independent prognostic
variable warranting further research. An earlier study found that
occludin was also lost in polygonal (unpolarized) cells of Gleason
grades 4 and 5, but remained expressed in all cells facing a lumen in all
grades of cancer [105]. Downregulation of occludin in prostate cancer
was thus seen to be associated with loss of cell polarity and coincides
with the formation of the complex glandular architecture of Gleason
grade 4 pattern or complete loss thereof in Gleason grade 5 patterns.
6.8. Lung cancer
6.8.1. Transmembrane proteins in lung cancer
Paschoud et al. [106] found a statistically signiﬁcant correlation
between diagnosis and positivity of tumors with either claudin-1 or
claudin-5. Squamous cell carcinomas and basal cells of bronchial
epithelium were positive for claudin-1 and negative for claudin-5,
whereas adenocarcinomas, normal cylindrical cells and pneumocytes
were positive for claudin-5 and negative for claudin-1, suggesting
different pathways in tumor development and progression. Claudin-4
and ZO-1 staining were detected in both types of tumors, whereas
cingulin was not detected in squamous cell carcinomas. In squamous
cell carcinomas, there were statistically signiﬁcant decreases in the
mRNA levels of JAM-1, occludin, claudin-3, claudin-4, claudin-7,
cingulin, ZO-2 and ZO-3, and an increase in claudin-1 mRNA. In
adenocarcinomas, when transcript levels were compared with
bronchial cells, there were also statistically signiﬁcant decreases in
the mRNA levels of claudin-1, claudin-3, claudin-4, claudin-7, ZO-2
and ZO-3. These results indicate that characterization of TJ protein
expression in human lung tumors can be an additional diagnostic tool
and provide new insights on their histogenesis. In small cell lung
carcinomas, differential expression was conﬁrmed for claudin-1 in
82.1% of lung tumor tissues, by quantitative real-time reverse
transcription-PCR analysis [107].
An earlier study of 68 lung carcinomas and surrounding normal
lung tissues found that in normal lung tissues occludin strongly
stained the apicoluminal borders of the bronchial/bronchiolar
epithelia and bronchial glands as a dot or short line [108]. Occludin
also stained the intercellular borders of alveolar epithelia. In cancer
cells that faced lumina of all adenocarcinomas, regardless of grade,
including bronchioloalveolar carcinomas, occludin showed an expres-
sion pattern identical to that of the normal bronchial and alveolar
epithelia. Occludin reactivity was not noted in any cases of squamous
cell carcinoma, large cell carcinoma, small cell carcinoma, or large cell
neuroendocrine carcinoma [108]. It was suggested that occludin could
serve as an immunohistochemical indicator of the “true” glandular
differentiation that forms tubulo-papillary structures in human lung
carcinoma tissues.
6.9. Melanoma
6.9.1. Transmembrane proteins in melanoma cancer
Leotela et al. [109] used tissue microarray technology to reveal that
claudin-1 was overexpressed in melanoma, and aberrantly expressed
in the cytoplasm of malignant cells, suggesting a role other than
transport. Indeed, melanoma cells in culture demonstrate no TJ
function. It has been shown that protein kinase C (PKC) can affect
expression of claudin-1 in rat choroid plexus cells, and there was a
correlation between levels of activated PKC and claudin expression. It
was subsequently found that PKC activation by PMA caused an
increase in claudin-1 transcription and protein. Inhibition of PKC
signalling in cells with high claudin-1 expression resulted in
decreased claudin-1 expression. Transient transfection of melanoma
cells with claudin-1 increased MMP-2 secretion and activation, and
subsequently, motility of melanoma cells. Conversely, knockdown of
claudin-1 resulted in the inhibition of motility, as well as decreases in
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progression.
6.10. Pancreatic cancer
6.10.1. Transmembrane proteins in pancreatic cancer
There has been found to be a correlation between TJ and cancer cell
dissociation, as well as the involvement of MEK2 in regulation of TJ in
cell dissociation of pancreatic cancer [110]. After incubation with
conditioned medium of PC-10 cells, plasma membrane distribution of
claudin-1 was obviously disrupted, and expressions of MEK2 and p-
MEK1/2, as well as dissociation of cell colonies, were signiﬁcantly
induced in PC-1 and CAPAN-2 cells. However, U0126 (a MEK1/2
inhibitor) treatment apparently induced the plasma membrane
distribution of claudin-1 and aggregation of single cells in PC-1 and
AsPC-1 cells, synchronously seriously suppressed MEK2 and p-MEK1/
2 expression. Arrangement of expression and distribution of claudin-1
is closely related to cell dissociation status in pancreatic cancer cells
through MEK2 activation.
Borka et al. [111] analyzed protein and mRNA expressions of
different claudins in human pancreatic endocrine tumors and ductal
adenocarcinomas. Normal acini and ducts showed strong claudins-1, -
3, -4, and -7 and scattered claudin-2 protein expressions, while
Langerhans islands revealed only claudin-3 and -7 expressions.
Claudin-2 expression was found in the half of ductal adenocarcino-
mas, while the vast majority of endocrine tumors were negative.
Claudins-1, -4, and -7 immunohistochemistry were positive in all
adenocarcinomas, whereas endocrine tumors were completely nega-
tive for claudins-1 and -4. Claudins-3 and -7 proteins were detected in
all endocrine tumors, while claudin-13 in ductal adenocarcinomas
was negative. The mRNA expression of claudins showed differences
between endocrine tumors and ductal adenocarcinomas, with high
expressions of claudin-3 in endocrine tumors and claudin-4 in ductal
carcinomas which make them attractive targets for adjuvant therapy.
6.10.2. Peripheral plaque proteins in pancreatic cancer
An early study investigating ZO-1 in pancreatic cancer [112]
showed that expression of ZO-1 mRNA was increased sixfold in PDAC
samples in comparison with normal samples. Confocal microscopy
revealed the presence of ZO-1 in the apical and apicolateral areas of
ductular cells in the normal pancreas. Similarly, in CP, ZO-1 was
localized at apical and apicolateral areas of small proliferating
ductular cells and large metaplastic ducts. In PDAC, however, ZO-1
expression was observed irrespective of whether the cancer cells
formed duct-like structures or exhibited a diffuse inﬁltrating pattern.
Metastatic pancreatic cancer cells within lymph nodes display
variable staining patterns for ZO-1, ranging from apical and
apicolateral to a diffuse membranous staining suggesting that ZO-1
is overexpressed in PDAC and raise the possibility that this
overexpression may confer a metastatic advantage to pancreatic
cancer cells.
A later study [113] investigated the translocation of ZO-1 and the
activation of epidermal growth factor receptor (EGFR) to demonstrate
the involvement and correlation of TJ protein translocation and EGFR
activation in the cell dissociation and subsequent invasion of
pancreatic cancer. The obvious translocation of cell–cell junction
localized ZO-1 protein to the cytoplasm and nucleus, simultaneous
activation of EGFR, as well as the dissociation of cell colonies of non-
dissociated pancreatic cancer cells were induced by dissociation factor
treatment. However, EGFR inhibitor, AG1478, treatment signiﬁcantly
induced the redistribution of ZO-1 protein to the sites of cell–cell
junction and the cell aggregation, as well as simultaneous suppression
of EGFR activation in both the dissociated and the non-dissociated
pancreatic cancer cells. In addition, AG1478 treatment markedly
enhanced the in vitro invasion of non-dissociated pancreatic cancer
cells. Translocation of TJ protein ZO-1 as thus found to be closelyinvolved in the induction of invasion through EGFR activation in
pancreatic cancer cells.
An early study [114] identiﬁed a fragment present in normal
pancreatic duct cells that is not expressed in pancreatic duct
carcinoma cells. Sequence analysis showed an 88% and 82% identity,
respectively, to the cDNA of the canine and humanTJ ZO-2 gene. Semi-
quantitative RT-PCR analysis of human ZO-2 revealed a striking
difference in the expression of various regions of the ZO-2 transcript in
normal and neoplastic cells and the presence of an abnormality at the
5′-end of mRNA. RACE analysis identiﬁed 2 human ZO-2 mRNAs that
encode proteins of different lengths, designated as ZO-2A and ZO-2C.
The difference between the 2 forms of ZO-2 is the absence of 23 amino
acid residues at the N terminus of ZO-2C compared with ZO-2A.
Although ZO-2C was expressed in normal pancreatic cells and a
majority of neoplastic tissues analyzed, ZO-2A was undetectable
except in one case in all of the pancreatic adenocarcinomas analyzed.
6.11. Other cancers
6.11.1. Multi-cancer studies
As the coxsackie and adenovirus receptor (CAR) is involved in
epithelial cell TJ [115], the authors examined CAR's role in tumor
metastasis using a B16 melanoma and CT26 colon adenocarcinoma
model of experimental metastasis. In lung metastasis, the colony
number of B16 cells stably expressing CAR (B16CAR) was signiﬁcantly
lower than that of the control CAR-negative B16 cells. B16 and CT26
cells transiently expressing CAR, which were transduced with
adenovirus (Ad) vector expressing CAR, also reduced lung metastasis,
suggesting that CAR plays a role in the early stage of metastasis. CAR
expression signiﬁcantly decreased the accumulation of B16 cells in the
lung after i.v. injection and the migration in vitro. CAR expression
reduced expression of alpha (v), alpha (4), beta (3) and beta (1)
integrin, which play important roles in attachment to cells or
basement membrane. CAR expression likely acts as a metastatic
suppressor in these cancer types.
6.11.2. Malignant brain tumors and the blood–brain-barrier (BBB)
Malignant brain tumors cause cerebral edema because they have
leaky endothelial TJ, which allow plasma ﬂuid to enter the brain from
the microvessel lumen [116]. In order to identify molecular abnorm-
alities in tumor endothelial TJ, occludin expression in microvessels
from adult human non-neoplastic brain tissue was investigated. The
proportions of microvessels immunolabelling for occludin were N2/3
in 5/5 non-neoplastic brain tissue samples, N1/3 in 5/5 low grade
(Daumas-Duport I or II) astrocytomas and b1/3 in 5/5 high grade (III
or IV) astrocytomas and 6/6 metastatic adenocarcinomas. Six non-
neoplastic brain tissue immunoblots gave a 55-kDa occludin band,
three low-grade astrocytomas gave 55-kDa and60-kDa bands,13 high-
grade astrocytomas gave 60-kDaor no band and four adenocarcinomas
did not give an occludin band. Expression of 55-kDa occludin inversely
correlated with the presence of contrast enhancement on computed
tomograms. Electron microscopy showed open endothelial TJ in 0/2
non-neoplastic human brain specimens and 2/2 high-grade astro-
cytomas. It is thought that loss of 55-kDa occludin expression in
human brain tumors may contribute to endothelial TJ opening.
Septic encephalopathy is associated with breakdown of the blood–
brain barrier and cerebral edema [117]. These features are also
common properties of brain tumors. Perimicrovessel edema, disrup-
tion of associated astrocyte end feet and neuronal injury occur in a
porcine model of acute septic encephalopathy. The adrenergic system
has been implicated in the inﬂammatory response to sepsis and may
play a role in controlling blood–brain barrier permeability, since the
β2-adrenoceptor agonist dopexamine inhibits perimicrovessel edema
formation whereas the α1-adrenoceptor agonist methoxamine
provokes it. Electron microscopy revealed TJ opening in high-grade
astrocytoma microvessels. Expression of the TJ protein occludin is
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correlated with the degree of cerebral edema [117]. Normal astrocytes
secrete factors that induce barrier properties in endothelial cells,
whereas high-grade astrocytomas secrete vascular endothelial growth
factor, which stimulates angiogenesis, down regulates occludin and
increases endothelial cell permeability [117]. The water channel
protein aquaporin-4 is normally expressed in astrocyte foot processes
around cerebral microvessels. Its expression is massively up-regulated
in high-grade astrocytoma and around metastatic adenocarcinoma.
There is a signiﬁcant correlation between aquaporin-4 expression and
the degree of cerebral edema, but it is not clear whether increased
aquaporin-4 expression enhances edema formation or clearance.
These results suggest that the pathophysiology of brain edema is
multifactorial, but that there may be common processes operating
regardless of the aetiology [117].
The quality of the blood–brain barrier (BBB), represented mainly
by endothelial TJ is now believed to be dependent on the brain
microenvironment and inﬂuenced by the basal lamina of the
microvessels [118]. In the highly vascularized glioblastoma multi-
forme (GBM), a dramatic increase in the permeability of blood vessels
is observed but the nature of basal lamina involvement remains to be
determined. Agrin, a heparan sulphate proteoglycan, is a component
of the basal lamina of BBB microvessels, and growing evidence
suggests that it may be important for the maintenance of the BBB
[118]. This study provided the ﬁrst evidence that agrin is absent from
basal lamina of tumor vessels if the TJ molecules occludin, claudin-5
and claudin-1 were lacking in the endothelial cells [118]. If agrin was
expressed, occludin was always localized at the TJ, claudin-5 was
frequently detected, whereas claudin-1 was absent from almost all
vessels. Furthermore, despite a high variability of vascular pheno-
types, the loss of agrin strongly correlated with the expression of
tenascin, an extracellular matrix molecule which has been described
previously to be absent in mature non-pathological brain tissue and to
accumulate in the basal lamina of tumor vessels. These results support
the view that in human GBM, BBB breakdown is reﬂected by the
changes of the molecular compositions of both the endothelial TJ and
the basal lamina [118].
The development of peritumoral edema is thought to be due to
extravasation of plasma water and macromolecules through a
defective blood–brain barrier (BBB), but the exact mechanism by
which occurs is poorly understood [119]. Biopsies of 25 patients with
pathological diagnosis of astrocytic tumors were examined. Both open
and close TJ were observed in the micro-blood vessels, inclusive in a
same tumor. Cytoskeletal disorganization associated with disinte-
grated perijunctional actin ﬁlaments was seen. The paracellular space
showed enlargement and commonly occupied by ﬂuid proteinaceous,
endothelial cells display oncotic and ischemic changes; basal lamina
reveals enlargement, edema, vacuolization and collagen ﬁbers
disposed in irregular array. Pericytes exhibited edema and phagocy-
tozed material, astrocytic perivascular-feet showed signs of oncosis
and necrosis, cooption vessels totally surrounding by neoplastic cells
also were seen [119]. The ultrastructural abnormalities observed in
both junctional complexes and vascular microenvironment suggest a
multi-factorial pathobiology process, probably hypoxia intratumoral,
calcium overload in endothelial cells, and degradative effects of
metalloproteinases over the basal membrane appear as determinant
factors that leading to structural modiﬁcations of junctional com-
plexes, therefore, treatment with both HIF-1a and metalloproteinases
inhibitors possibly can contribute with the pharmacological handling
of the peritumoral edema associated with astrocytic tumors [119].
6.11.3. Other cancers and associated endothelium
Hepatocyte growth factor (HGF) is a multi-function cytokine that
has been shown to regulate the expression of cell adhesion molecules
in human endothelial cells. It is also a key cytokine in the development
and progression of cancer, particularly during metastasis. NK4 is avariant of HGF that has already been shown to be antagonistic to HGF.
The study by Martin et al. [6] shows that HGF decreased transen-
dothelial resistance and increased paracellular permeability in human
vascular endothelial cells that such effects can be inhibited by addition
of the NK4 variant. In addition, HGF-stimulated invasion of endothe-
lium by breast cancer cells was inhibited by the addition of NK4.
Western blotting revealed that HGF/SF decreased the protein level,
and increased tyrosine phosphorylation of ZO-1, but did not cause a
change in level of occludin or claudin-1, both molecules involved in TJ
function. RT-PCR revealed that addition of HGF/SF caused no change
in signal for claudin-5 or junctional adhesion molecule (JAM), but
there was a decrease in the signal for claudin-1. NK4 was also able to
prevent the decrease in levels of ZO-1 protein by HGF/SF indicating
that TJ permeability can be modulated therapeutically.
Disruption of TJ can lead to leaky vascular bed and potentially to
edema and swelling of tissues, the [120] aetiology of mastalgia. These
changes may also cause vascular spread of cancer cells. In human
endothelial cells GLA (gamma-linolenic acid), I (iodine), and Se
(selenium) individually increased transendothelial resistance in the
presence of 17beta-estradiol (17β-estradiol), which causes leakage of
endothelial cells by disruption of TJ. The combination of all three
agents also had a signiﬁcant effect on TER (Fig. 4). Addition of GLA/Se/
I reduced PCP of the endothelial cells. Treatment with GLA/Se/I
reversed the effect of 17b-estradiol in reducing TER and increasing
PCP. Immunoﬂuorescence revealed that after treatment with Se/I/
GLA over 24 h there was increasing relocation to endothelial cell–cell
junctions of the TJ proteins claudin-5, occludin, and ZO-1 [120].
Interestingly, this relocation was particularly evident with treatments
containing I when probing with claudin-5 and those containing Se for
occludin. There was a small increase in overall protein levels when
examined by Western blotting after treatment with GLA/Se/I when
probed with claudin-5 and occludin. It was observable that GLA, I, and
Se alone, or in combination are able to strengthen the function of TJ in
human endothelial cells, by way of regulating the distribution of
claudin-5, occludin, and ZO-1. Interestingly, this combinationwas also
able to completely reverse the effect of 17β-estradiol in these cells
[120].
6.11.4. Oral cancer
Oku et al. [121] investigated whether claudin-1 regulated invasion
activity in oral squamous cell carcinoma (OSC) cells. Compared with
OSC-7, both OSC-4 and NOS-2 more strongly expressed claudin-1 and
possessed high activities of MMP-2 andMMP-9. Tumors formed in the
tongues of SCID mice xenografted with OSC-4, NOS-2, and OSC-7
immunohistochemically revealed strong, moderate, and weak expres-
sion of laminin-5; 2 chains, respectively, and laminin-5; 2 chains were
secreted in the conditionedmedium of the cancer cells in parallel with
the in vivo results. Claudin-1 siRNA largely suppressed the invasion of
OSC-4 and decreased the activation of MMP-2, the expression of
membrane-type MMP-1 (MT1-MMP), and the cleavage of laminin-
5;2. In addition, not only antibodies against MT1-MMP and epidermal
growth factor receptor (EGFR) but also MMP-2 and EGFR inhibitors
strongly suppressed the invasion activity of OSC-4. These results
suggest that claudin-1 upregulates cancer cell invasion activity
through activation of MT1-MMP and MMP-2, which results in
enhanced cleavage of laminin-5;2 chains.
6.11.5. Liver and hepatocellular cancer
VEGF induces a marked loss of pseudocanaliculi and disruption of
occludin-delineated tight junctions in HepG2 cells. This effect of VEGF
was mimicked by phorbol-12-myristate-13-acetate (PMA) and was
sensitive to protein kinase C (PKC) inhibition by Gö6850. VEGF also
induced the translocation of the PKCa-isoform to the plasma-
membrane, but had no effect on the activity of Erks and p38MAPK.
Sections from surgically removed human HCC showed expression of
VEGF in the tumor and occludin disassembly in normal liver
Fig. 4. Effect of iodine, selenium and GLA on the location of claudin-5 (A), occludin (B) and ZO-1 (C) in human endothelial cells.
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disruption of TJ in a PKC-a dependentmanner. In addition to its known
angioneogenic properties, the authors suggest that VEGFmay promote
HCC spreading into normal liver parenchyma. The data may provide
another rationale for the use of VEGF antagonists for tumor therapy.
Ip et al. [123] investigated claudin-10 function in two different
hepatocellular carcinoma cell lines observing that overexpression of
claudin-10 conferred malignant phenotypes to hepatocellular carci-
noma cells, Hep3B, which lack claudin-10 expression, by promoting
cancer cell survival, motility, and invasiveness. More importantly,
MMP2 was up-regulated. Increase in mRNA transcription and protein
expression of membrane type 1-MMP (MT1-MMP) was also observed
in the claudin-10 transfectants, and in addition, claudin-1, claudin-2,
and claudin-4 were up-regulated in claudin-10 overexpression
transfectants, indicating that the expression of claudin-10 in cancer
cells might affect the expression levels of its family members. On the
contrary, small interfering RNA-based knockdown of claudin-10 in
HLE, an invasive cell line with high level of claudin-10 expression,
abolished invasion and strongly decreased activation of MMPs and
claudin member's expression.
6.11.6. Synovial cancer
Synovial sarcoma, a soft tissue sarcoma that develops in adults, is
pathologically subclassiﬁed into monophasic spindle synovial sar-
coma and biphasic synovial sarcoma with epithelial components
[124]. Expression proﬁles of 21 claudins in 17 synovial sarcoma tumor
samples, including 9 biphasic tumors, identiﬁed claudin-4, claudin-7,
and claudin-10 as biphasic tumor-related claudins, and immunohis-
tochemical analyses demonstrated the localization of these claudins in
the epithelial component in biphasic tumors, with claudin-7 the most
closely associated with the epithelial component. The mRNA expres-
sion and protein localization of claudin-7 coincided with those of the
ELF3, an epithelia-speciﬁc member of the Ets family of transcription
factors. Inhibition of ELF3 expression by small interfering RNA
simultaneously down-regulated the mRNA expression of the clau-
din-7 gene and the introduction of ELF3 expression in claudin-7-
negative cell lines induced mRNA expression of the claudin-7 gene.
Therefore, the induction of claudin-7 expression by ELF3 appears
critical to the formation of the epithelial structures in biphasic
synovial sarcoma [124].
6.11.7. Thyroid cancer
In ninety-one thyroid neoplasms (15 follicular adenomas, 15
follicular carcinomas, 26 papillary carcinomas, 16 papillary micro-
carcinomas, 8 medullary carcinomas, 3 poorly differentiated carcino-
mas, and 8 undifferentiated carcinomas) occludin was mainly
expressed in the form of intracytoplasmic vesicles, whereas all
claudins tested exhibited membranous immunostaining [125]. Thir-
teen out of 15 follicular adenomas, 10/15 follicular carcinomas, 24/26
papillary carcinomas,15/16 papillarymicrocarcinomas,1/8medullary
carcinomas, 2/3 poorly differentiated carcinomas and 2/8 undiffer-
entiated carcinomas exhibited claudin-1 expression, whereas claudin-
4 was expressed in 13/15,12/15, 23/26,13/16, 7/8, 2/3 and 2/8 of the
tumors, respectively, and claudin-7 expressionwas found in 67, 33, 73,
69, 25, 0 and 13% of the cases, respectively [125]. Occludin was
expressed in 100% follicular adenomas, 80% follicular carcinomas, 96%
papillary carcinomas, 50% papillary microcarcinomas, 50% medullary
carcinomas, 33% poorly differentiated carcinomas and 88% undiffer-
entiated carcinomas. Occludin expression was reduced in papillary
microcarcinomas, medullary carcinomas and poorly differentiated
carcinomas. All claudins exhibited reduced expression in undiffer-
entiated carcinomas [125]. Claudin-1 was additionally reduced in
medullary carcinomas and claudin-7 in follicular, medullary and
poorly differentiated carcinomas. A correlation between loss of
claudin-1 expression and worse disease-free survival was noted on
univariate analysis. The authors suggest that dedifferentiation of thethyroid carcinomas is accompanied by reduction in claudin-1, -4 and -
7 expression. A differential expression of TJ proteins in the different
histologic types of thyroid gland is noted. Additionally, claudin-1
expression may be an important prognostic indicator of recurrence in
thyroid carcinomas [125].
6.11.8. Neuroﬁbroma
In a study of 16 neuroﬁbromas from 12 patients with neuroﬁ-
bromatosis type 1 (NF1) cell–cell contacts with typical ultrastructural
morphology of TJ were seen between adjacent perineurial cells
surrounding the small nerves and between contacting perineurial cell
processes embedded in tumor stroma [126]. Immunohistochemistry
showed expression of claudin-1, claudin-3, and ZO-1 in the inter-
cellular junctions of a subpopulation of tumor cells. Occludin was
present mainly in perineurium and claudin-5 localized to the blood
vessels. Claudin-1 positive cells were also positive for type IV collagen
and epithelial membrane antigen but not for S-100 protein a labelling
pattern consistent with a perineurial cell phenotype. Using claudin-1
as a marker, the authors showed that clusters of perineurial cells are
distributed around the rudimentary nerves within cutaneous neuro-
ﬁbromas and at the periphery of some neuroﬁbromas [126].
6.11.9. Testicular cancer
In normal seminiferous epithelium, specialized TJ between Sertoli
cells constitute the major component of the blood–testis barrier [127].
Sertoli cells associated with CIS exhibit impaired maturation status,
but their functional signiﬁcance remains unknown. In normal tubules,
ZO-1 and ZO-2 immunostaining was observed at the blood–testis
barrier region of adjacent Sertoli cells. Within CIS tubules, ZO-1 and
ZO-2 immunoreactivity was reduced at the blood–testis barrier
region, but spread to stain the Sertoli cell cytoplasm. Western blot
analysis conﬁrmed ZO-1 and ZO-2, and their respective mRNA were
shown by RT-PCR. In conclusion, Sertoli cells associated with CIS show
an altered distribution of ZO-1 and ZO-2 and lose their blood–testis
barrier function [127].
7. Prevention of metastasis: promising new targets for cancer
diagnosis and therapy
It is apparent from this overview of the studies carried out on TJ
function and aberrant expression in cancer, that individual compo-
nents within the TJ complex offer intriguing and novel targets for the
prognosis, detection and, indeed, possible modes of treatment for
patients with cancer. Until now, most of the work has concentrated on
the use of claudins, and the reader is directed to a number of reviews
showcasing this [128–130]. Of interest is the work carried out by
Skrovanek et al. [131] who found that restriction of sulfur-containing
amino acids (SCAA) in LLC-PK (1) renal epithelial cells resulted in
reduction of methionine by 90%. Cell growth and differentiation were
maintained, and both conﬂuent cell density and transepithelial short
circuit current were unaffected. Occludin and claudins-1 and -2 did
not have altered expression, however, claudins-3 and -7 were
signiﬁcantly decreased and claudins-4 and -5 were markedly
increased. The functional result of these structural changes was
improved barrier function. In contrast to normal cells, tumor cells
have absolute requirement for methionine. In animal models,
methionine restriction limits tumor growth and reduces tumor
volume. However, interruption of methionine restriction induces the
regrowth of tumors. Moreover methionine restriction induces cell
modiﬁcations suggesting it had a use in associationwith conventional
chemotherapy [132]. That there is a link between methionine
restriction and TJ protein expression leads to interesting possibilities
for future therapies. It might be anticipated that as further work sheds
light on the seemingly diverse yet vital functions of the other TJ
molecules, there will be increasing possibilities in utilising the TJ
components as targets for therapy to prevent cancer metastasis.
889T.A. Martin, W.G. Jiang / Biochimica et Biophysica Acta 1788 (2009) 872–8918. Summary
TJ were ﬁrst described as having altered form and function in
tumor cells and tissues over thirty years ago [133,134]. It is
increasingly evident from the rapidly growing research in this area,
that the TJ has a vital role to play during cancermetastasis. The claudin
family group has been most explored; however, it is vital that the
other transmembrane and peripheral components attract as much
attention. The TJ and changes in barrier function appear to be part of
an essential mechanism that is awry during cancer metastasis;
whether up-regulation promotes cell dissemination, or whether
down-regulation, causing dismantling of the TJ structure leading to
loss of polarity, loss of contact inhibition, uncontrolled growth,
detachment and invasion of cancer cells and hence successful
penetration of the endothelium (intravasation and extravasation) by
aberrant cell surface expression (direct interaction) or via secretion of
regulatory/degradative substances by the cancer cells. Moreover,
dysregulation of the TJ can also lead to potentially exciting markers for
the prognosis of a number of tumor types. Although TJ proteins have
yet to be proven true suppressor proteins, all these data suggest that
the TJ is vital to the prevention of successful cancer cell metastasis and
further research should provide answers to using TJ as an essential
point for intervention during the metastatic cascade.
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